Theoretical basis and progress of fecal microbiota transplantation in metabolic associated fatty liver disease / 中华临床营养杂志
Chinese Journal of Clinical Nutrition
; (6): 244-250, 2023.
Article
en Zh
| WPRIM
| ID: wpr-1024643
Biblioteca responsable:
WPRO
ABSTRACT
Metabolic associated fatty liver disease (MAFLD) is a cluster of chronic, progressive diseases with an increasing prevalence rate worldwide. MAFLD has become the leading cause of chronic liver disease around the world, for which approved therapy is currently lacking. In recent years, growing evidence has demonstrated the close link between gut microbiome dysbiosis and MAFLD. The generation of pro-inflammatory bacterial components and metabolites is susceptible to the changes in the abundance, diversity, and ratio of intestinal bacteria, which could accelerate the progress of MAFLD through the gut-liver axis. As a new therapeutic strategy, fecal microbiota transplantation (FMT) is the transplantation of flora from the intestines of healthy people into the gastrointestinal tract of patients, to directly correct intestinal flora disorders and alter bacterial metabolites. FMT has been widely used in the treatment of Clostridium difficile infections and inflammatory bowel disease. The role of FMT in the treatment of MAFLD has also been explored. However, studies about FMT in MAFLD are overall scarce and the mechanism of action and the therapeutic effect of FMT on MAFLD remains ambiguous. We summarized the existing evidence on the potential molecular mechanism and effectiveness related to FMT in MAFLD.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Clinical Nutrition
Año:
2023
Tipo del documento:
Article